SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
September 12, 2025 16:30 ET | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,…
September 12, 2025 07:00 ET | Source: Cullinan Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics,…
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced…
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…
Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage…
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…
August 08, 2025 19:54 ET | Source: XORTX Therapeutics Inc. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR…
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…
July 29, 2025 17:00 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina…